HER2 significantly influences the tumour microenvironment (TME) through various mechanisms, creating a niche that supports tumour progression, immune evasion, and therapeutic resistance.
First-pass extracted concept
tumour microenvironment modulation by HER2 in oesophagogastric adenocarcinoma
Evidence Snippets
Supporting Sources
Linked Claims
HER2 modulates the tumour immune microenvironment by downregulating MHC molecules and recruiting immunosuppressive cells including regulatory T cells and tumour-associated macrophages.
HER2 also modulates the tumour immune microenvironment (TIME) by downregulating MHC molecules and recruiting immunosuppressive cells, including regulatory T-cells (T-reg) and tumour-associated macrophages (TAMs)...
In HER2-positive oesophagogastric adenocarcinoma, HER2 influences the tumour microenvironment in ways that support tumour progression, immune evasion, and therapeutic resistance.
HER2 significantly influences the tumour microenvironment (TME) through various mechanisms, creating a niche that supports tumour progression, immune evasion, and therapeutic resistance.
In HER2-positive oesophagogastric adenocarcinoma, aberrant PI3K/AKT and MAPK/ERK signalling enhance tumour cell survival and proliferation.
In HER2-positive EGA, aberrant signalling pathways, such as PI3K/AKT and MAPK/ERK, enhance tumour cell survival and proliferation...
In HER2-positive oesophagogastric adenocarcinoma, upregulation of VEGF fosters vascularization that supports tumour metabolic demands and proliferation.
upregulation of angiogenic factors like VEGF fosters vascularization, meeting a tumour's metabolic demands and facilitating its proliferation.
A pro-inflammatory, immunosuppressive microenvironment in HER2-positive oesophagogastric adenocarcinoma underpins resistance to HER2-targeted therapies.
Together, these factors foster a pro-inflammatory, immunosuppressive microenvironment that underpins resistance to HER2-targeted therapies.